natgillin/translations-raw huggingface dataset:
De hyppigste bivirkninger ved Tyverb (som optræder hos flere end 25 % af patienterne) er udslæt og bivirkninger, der påvirker mave-tarmsystemet (f.eks. diarré, kvalme og opkastning).
The most common side effects with Tyverb (seen in more than 25% of patients) are rash and side effects affecting the stomach and gut (such as diarrhoea, nausea (feeling sick) and vomiting).
De hyppigste bivirkninger ved Valdoxan (som optræder hos mellem 1 og 10 patienter ud af 100) er hovedpine, svimmelhed, søvntrang, søvnløshed, migræne, kvalme, diarré, forstoppelse, mavepine, opkastning, øget svedafsondring, rygsmerter, træthed, forhøjede leverenzymtal og angst.
The most common side effects with Valdoxan (seen in between 1 and 10 patients in 100) are headache, dizziness, somnolence (sleepiness), insomnia (difficulty sleeping), migraine, nausea (feeling sick), diarrhoea, constipation, abdominal pain (stomach ache), vomiting, hyperhidrosis (excessive sweating), back pain, fatigue (tiredness), increases in liver enzymes and anxiety.
De hyppigste bivirkninger ved Vectibix (som optræder hos flere end to ud af 10 patienter) er diarré, kvalme, opkast, forstoppelse, mavesmerter, træthed, pyreksi (feber), appetitløshed, paronychi (infektion i neglelejet), udslæt, acnelignende dermatitis (betændelse i huden, som ligner acne), pruritus (kløe), erythem (rødfarvning af huden) og tør hud.
The most common side effects with Vectibix (seen in more than 2 patients in 10) are diarrhoea, nausea (feeling sick), vomiting, constipation, abdominal pain (stomach ache), fatigue (tiredness), pyrexia (fever), lack of appetite, paronychia (nail bed infection), rash, acneiform dermatitis (skin inflammation resembling acne), pruritus (itching), erythema (reddening of the skin) and dry skin.
De hyppigste bivirkninger ved Viagra er hovedpine, rødmen, dyspepsi (fordøjelsesbesvær), synsforstyrrelser, herunder forvrænget farvesyn og sløret syn, nasal kongestion (stoppet næse), svimmelhed, kvalme og hedeture.
The most common side effects with Viagra are headache, flushing, dyspepsia (indigestion), visual disorders, including visual colour distortion and blurred vision, nasal congestion (blocked nose), dizziness, nausea and hot flush.
De hyppigste bivirkninger ved Vimpat (som optræder hos flere end 1 ud af 10 patienter) er svimmelhed, dobbeltsyn, hovedpine og kvalme.
The most common side effects with Vimpat (seen in more than 1 patient in 10) are dizziness, headache, diplopia (double vision) and nausea (feeling sick).
De hyppigste bivirkninger ved Viread (som optræder hos flere end 1 ud af 10 patienter) er kvalme, opkastning, diarré, svimmelhed og hypofosfatæmi (lavt indhold af fosfat i blodet), udslæt og asteni (kraftesløshed).
The most common side effects with Viread (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, diarrhoea, dizziness, hypophosphataemia (low levels of phosphate in the blood), rash and asthenia (weakness).
De hyppigste bivirkninger ved Visudyne (som optræder hos mellem 1 og 10 ud af 100 patienter) er forhøjede kolesterolmængder i blodet, svært nedsat synsskarphed, synsforstyrrelser (såsom uklart syn, sløret og uklart syn eller lysglimt), fejl i synsfeltet (såsom små områder med nedsat syn, grå eller mørke ringe og sorte pletter), kvalme, lysoverfølsomhedsreaktioner (reaktioner, der ligner solskoldethed, efter at have været udsat for lys), reaktioner på injektionsstedet (smerter, hævelse, inflammation og væskeudsivning fra venerne), asteni (muskelslaphed) og infusionsrelaterede smerter (hovedsageligt rygsmerter).
The most common side effects with Visudyne (seen in between 1 and 10 patients in 100) are hypercholesteraemia (high blood cholesterol levels), hypersensitivity (allergic reactions), severely reduced visual acuity (very unclear vision), visual impairment (such as unclear vision, blurred fuzzy vision or flashes of light), defects in the visual field (such as small areas of reduced vision, grey or dark haloes, and black spots), dyspnoea (shortness of breath), nausea (feeling sick), photosensitivity reactions (sunburn-like reactions following exposure to light), reactions at the injection site (pain, swelling, inflammation and leakage of fluid from the veins), asthenia (weakness), infusion-related pain (mainly chest and back pain), syncope (fainting), headache and dizziness.
De hyppigste bivirkninger ved Volibris (som optræder hos flere end 1 ud af 10 patienter) er hovedpine (herunder sinushovedpine og migræne), perifere ødemer (hævelse, især af ankler og fødder) og væskeansamling.
The most common side effects with Volibris (seen in more than 1 patient in 10) are headache (including sinus headache and migraine), peripheral oedema (swelling, especially of the ankles and feet) and fluid retention.
De hyppigste bivirkninger ved Votubia (som optræder hos flere end 1 ud af 10 patienter) er akne, stomatitis (betændelse i slimhinden), infektioner i de øvre luftveje (forkølelser), nasopharyngitis (betændelse i næse og hals), sinusitis (bihulebetændelse), otitis media (mellemørebetændelse), pneumoni (lungebetændelse), øget indhold af kolesterol, uregelmæssig menstruation og udeblivende menstruation.
The most common side effects with Votubia (seen in more than 1 in 10 patients) are acne, stomatitis (inflammation of the lining of the mouth), upper respiratory tract infections (colds), nasopharyngitis (inflammation of the nose and throat), sinusitis (inflammation of the sinuses), otitis media (infection of the middle ear), pneumonia (infection of the lung), increased blood levels of cholesterol, irregular menstruation (periods) and amenorrhoea (absence of periods).
De hyppigste bivirkninger ved Xadago (som kan forekomme hos op til 1 ud af hver 10 personer) er søvnløshed, vanskelighed ved at kontrollere bevægelserne (dyskinesi), søvnighed (somnolens), svimmelhed, hovedpine, forværring af eksisterende Parkinsons sygdom, grå stær (katarakt), blodtryksfald ved overgang til stående stilling (ortostatisk hypotension), kvalme og faldtendens.
The most common side effects with Xadago (which may affect up to 1 in 10 people) are insomnia (difficulty sleeping), dyskinesia (difficulty controlling movement), somnolence (sleepiness), dizziness, headache, worsening of existing Parkinson’s disease, cataract (clouding of the lens), orthostatic hypotension (drop in blood pressure when standing up), nausea (feeling sick) and falls.
De hyppigste bivirkninger ved Xalkori (som optræder hos flere end 1 ud af 4 patienter) er synsforstyrrelser, kvalme, diarré, opkastning, ødem (hævelse), forhøjede leverenzymtal i blodet, nedsat appetit, forstoppelse, svimmelhed, neuropati (smerte på grund af nerveskader) og træthed.
The most common side effects with Xalkori (seen in more than 1 in 4 patients) are vision problems, nausea (feeling sick), diarrhoea, vomiting, oedema (swelling), increases in liver enzymes in the blood, decreased appetite, constipation, dizziness, neuropathy (pain due to nerve damage) and fatigue.
De hyppigste bivirkninger ved Xarelto (som optræder hos mellem 1 og 10 patienter ud af 100) er anæmi, svimmelhed, hovedpine, blødning forskellige steder i kroppen, hypotension (lavt blodtryk), hæmatom (blodansamling under huden), mavesmerter, dyspepsi (halsbrand), kvalme, forstoppelse, diarré, opkastninger, kløe, udslæt, ekkymose (blå mærker), smerter i ekstremiteterne, nedsat nyrefunktion, feber, perifert ødem (hævelse, især af ankler og fødder), kraftesløshed og nedsat energi, forhøjet koncentration af visse leverenzymer i blodet og udsivning af blod eller væske fra operationssåret hos patienter, som gennemgår et kirurgisk indgreb.
The most common side effects with Xarelto (seen in between 1 and 10 patients in 100) are anaemia, dizziness, headache, bleeding in various parts of the body, hypotension (low blood pressure), haematoma (collection of blood under the skin), pain in the stomach and belly, dyspepsia (heartburn), nausea, constipation, diarrhoea, vomiting, pruritus (itching), rash, ecchymosis (bruising), pain in the extremities, decreased kidney function, fever, peripheral oedema (swelling, especially of the ankles and feet), decreased general strength and energy, increased levels of some liver enzymes in the blood and oozing of blood or fluid from the surgical wound in patients undergoing surgery.
De hyppigste bivirkninger ved Xgeva (som optræder hos flere end 1 ud af 10 patienter) er dyspnø (åndedrætsbesvær), diarré og smerter i muskler og knogler.
The most common side effects with Xgeva (seen in more than 1 patient in 10) are dyspnoea (difficulty breathing), diarrhoea and pain in the muscles and bones.
De hyppigste bivirkninger ved Xofigo (som kan forekomme hos flere end 1 ud af 10 patienter) er diarré, kvalme, opkastning og for lavt antal blodplader (trombocytopeni).
The most common side effects with Xofigo (which may affect more than 1 in 10 people) are diarrhoea, nausea (feeling sick), vomiting and thrombocytopenia (low blood-platelet counts).
De hyppigste bivirkninger ved Xtandi (som optræder hos flere end 1 ud af 10) er træthed, hovedpine, hedeture og højt blodtryk.
The most common side effects with Xtandi (which may affect more than 1 in 10 people) are tiredness, headache, hot flushes and hypertension (high blood pressure).
De hyppigste bivirkninger ved Zaltrap (som optræder hos flere end 20 ud af 100 patienter) er leukopeni og neutropeni (for lavt antal hvide blodlegemer i blodet, herunder den type, der bekæmper infektioner), diarré, proteinuri (protein i urinen), forhøjet indhold af leverenzymer (aspartat- og alanintransaminase) i blodet, stomatitis (mundbetændelse), træthed, trombocytopeni (for lavt antal blodplader), hypertension (for højt blodtryk), vægttab, nedsat appetit, epistaxis (næseblod), mavesmerter, dysfoni (taleforstyrrelser), forhøjet kreatininindhold i blodet (et tegn på nyreproblemer) og hovedpine.
The most common side effects with Zaltrap (seen in more than 20 patients in 100) are leucopenia and neutropenia (low levels of white cells in the blood, including the type that fight infections), diarrhoea, proteinuria (protein in the urine), increased blood levels of liver enzymes (aspartate and alanine transaminases), stomatitis (inflammation of the mouth), fatigue, thrombocytopenia (low blood platelet counts), hypertension (high blood pressure), weight loss, decreased appetite, epistaxis (nose bleeds), abdominal pain, dysphonia (speech disturbance), increases in creatinine in the blood (a marker of kidney problems), and headache.
De hyppigste bivirkninger ved Zebinix (som optræder hos flere end 1 ud af 10 patienter) er svimmelhed og søvntrang (søvnighed).
The most common side effects with Zebinix (seen in more than 1 patient in 10) are dizziness and somnolence (sleepiness).
De hyppigste bivirkninger ved Zelboraf (som optræder hos flere end 30 % af patienterne) omfatter ledsmerter, træthed, udslæt, lysoverfølsomhed, kvalme, hårtab og pruritus (kløe).
The most common side effects with Zelboraf (seen in more than 30% of patients) include arthralgia (joint pain), fatigue (tiredness), rash, photosensitivity reaction (sunburn-like reactions following exposure to light), nausea (feeling sick), alopecia (hair loss) and pruritus (itching).
De hyppigste bivirkninger ved Zerbaxa (som optræder hos op til 1 ud af 10 personer) er kvalme og hovedpine, forstoppelse, diarré og feber, sædvanligvis i mild og moderat grad.
The most common side effects with Zerbaxa (which may affect up to 1 in 10 people) are nausea (feeling sick), headache, constipation, diarrhoea and fever, which are generally mild or moderate.
De hyppigste bivirkninger ved Zydelig (som kan forekomme hos mere end 1 ud af 10 personer) er infektioner (herunder lungeinfektion forårsaget af Pneumocystis jirovecii, og cytomegalovirusinfektioner), lavt antal hvide blodlegemer af typen neutrofile (neutropeni), diarré, forhøjede leverenzymer i blodet, udslæt, feber og forhøjet indhold af fedtstoffer i blodet.
The most common side effects with Zydelig (which may affect more than 1 in 10 people) are infections (including lung infection caused by Pneumocystis jirovecii, and cytomegalovirus infections), neutropenia (low levels of neutrophils, a type of white blood cell), diarrhoea, increased liver enzymes in blood, rash, fever and increased blood fat levels.
De hyppigste bivirkninger ved Zykadia (som kan forekomme hos mere end 1 ud af 10 personer) er diarré, kvalme, opkastning, træthed, abnorme leverprøver, mavesmerter (abdominalsmerter), nedsat appetit, forstoppelse (konstipation), udslæt, forhøjet indhold af affaldsproduktet kreatinin i blodet (kan være tegn på nyreproblemer), problemer med spiserøret og lavt antal røde blodlegemer (anæmi).
The most common side effects with Zykadia (which may affect 1 or more people in 10) are diarrhoea, nausea (feeling sick), vomiting, tiredness, abnormal liver tests, abdominal pain (stomach ache), decreased appetite, constipation, rash, increases in the level of a waste product called creatinine in the blood (a possible sign of kidney problems), oesophageal disorder (problems affecting the gullet between mouth and stomach) and anaemia (low levels of red blood cells).
De hyppigste bivirkninger ved Zytiga (som optræder hos mere end 1 ud af 10 patienter) er urinvejsinfektion, hypokaliæmi (lavt kaliumindhold i blodet), hypertension (højt blodtryk) og perifere ødemer (hævelse af lemmerne på grund af væskeophobning).
The most common side effects with Zytiga (seen in more than 1 patient in 10) were urinary tract infection, hypokalaemia (low blood potassium levels), hypertension (high blood pressure) and peripheral oedema (swelling of the limbs due to fluid retention).
De hyppigste bivirkninger vedTafinlar alene (som kan forekomme hos over 15 % af patienterne), er papillomer (vorter), hovedpine, hoste, kvalme, opkastning, hyperkeratose (fortykket, grov hud), alopeci (hårtab), udslæt, feber, og træthed.
The most common side effects with Tafinlar alone (seen in more than 15% of patients) are papilloma (warts), headache, nausea, vomiting, hyperkeratosis (thickening and toughening of the skin), hair loss, rash, joint pain, fever and tiredness.
De hyppigste bivirkninger(≥1 %), der medførte seponering af en eller flere af FOLFIRI-komponenterne, var neutropeni (12,5 %), trombocytopeni (4,2 %), diarré (2,3 %) og stomatitis (2,3 %).
The most frequent (≥1%) ADRs leading to discontinuation of one or more components of FOLFIRI were: neutropenia (12.5%), thrombocytopenia (4.2%), diarrhoea (2.3%) and stomatitis (2.3%).
De hyppigste bivirkninger, der blev observeret hos patienter behandlet med Tarceva i studie BO18192 og BO25460, var udslæt og diarré (se tabel 2).
The most frequent ADRs seen in patients treated with Tarceva in studies BO18192 and BO25460 were rash and diarrhoea (see Table 2).
De hyppigste bivirkninger, der blev observeret i kliniske studier med Pandemisk influenzavaccine H5N1 MedImmune hos raske voksne, var hovedpine (25,4 %) og infektion i øvre luftveje (10,2 %).
The most common adverse reactions observed in clinical studies conducted with the Pandemic influenza vaccine H5N1 MedImmune in healthy adults was headache (25.4%) and upper respiratory infection (10.2%).
De hyppigste bivirkninger, der blev observeret med ambrisentan, var perifert ødem, væskeretention og hovedpine (inkl. sinushovedpine, migræne).
Peripheral oedema, fluid retention and headache (including sinus headache, migraine) were the most common adverse reactions observed with ambrisentan.
De hyppigste bivirkninger, der blev rapporteret hos den pædiatriske population, var okulær hyperæmi (16,9 %) og vækst af øjenvipper (6,5%).
The most frequent adverse reactions reported in the paediatric population were ocular hyperaemia (16.9%) and growth of eyelashes (6.5%).
De hyppigste bivirkninger, der er iagttaget under behandling af hepatisk VOD ved anvendelse før markedsføring, er blødning (bl.a. gastrointestinal blødning, pulmonal blødning og epistaxis), hypotension og koagulopati.
The most frequent adverse reactions observed during the treatment of hepatic VOD in pre-marketing use are haemorrhage (including but not limited to gastrointestinal haemorrhage, pulmonary haemorrhage and epistaxis), hypotension and coagulopathy.
De hyppigste bivirkninger, der er rapporteret efter markedsføringen under brug af rekombinant humant hyaluronidase i tilsvarende præparater, der blev indgivet subkutant til dispersion og absorption af subkutant administrerede væsker og lægemidler, var lette lokale reaktioner på infusionsstedet, såsom erytem og smerter.
The most frequent adverse reactions reported during post-marketing use of recombinant human hyaluronidase in similar formulations administered subcutaneously for the dispersion and absorption of subcutaneously administered fluids or medicinal products have been mild local infusion site reactions such as erythema and pain.
De hyppigste bivirkninger, der er rapporteret i forbindelse med overdosis i disse tilfælde, omfatter bradykardi, hypotension, oversedation, somnolens og hjertestop.
The most common adverse reactions reported in conjunction with overdose in these cases included bradycardia, hypotension, oversedation, somnolence and cardiac arrest.
De hyppigste bivirkninger, som forekom hos ≥ 3 % af de patienter, der fik behandling med Zinforo, var diarré, hovedpine, kvalme og pruritus og var generelt af let eller moderat sværhedsgrad.
The most common adverse reactions occurring in ≥ 3% of patients treated with Zinforo were diarrhoea, headache, nausea, and pruritus, and were generally mild or moderate in severity.
De hyppigste bivirkninger, som forekom hos ≥ 3 % af de patienter, der fik Zinforo, var kvalme, hovedpine og udslæt.
The most common adverse reactions occurring in ≥ 3% of patients treated with Zinforo were nausea, headache, and rash.
De hyppigste bivirkninger, som førte til seponering af behandlingen i pregabalin- gruppen, var svimmelhed og søvnighed.
The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.
De hyppigste bivirkninger, som førte til seponering af behandlingen i pregabalin-gruppen, var svimmelhed og somnolens.
The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.
De hyppigste bivirkninger, som kan forekomme hos 2 ud af 3 patienter, er diarré, hårtab og nedsat antal hvide blodlegemer (måles i en blodprøve) med eller uden feber
The most common side effects which may occur in about 2 out of 3 patients are diarrhoea, hair loss and a decrease in the number of your white blood cells (shown in a blood test) with or without fever.
De hyppigste bivirkninger, som ses med Daklinza kombineret med sofosbuvir med eller uden ribavirin, er træthed, kvalme og hovedpine.
The most common side effects reported with Daklinza in combination with sofosbuvir with or without ribavirin are fatigue (tiredness), nausea (feeling sick) and headache.
De hyppigste grad 3-4 bivirkninger (incidens ≥1 %) var stomatitis, amenoré, pneumoni, neutropeni, pyreksi, viral gastroenteritis og cellulitis.
The most frequent grade 3-4 adverse reactions (incidence ≥1%) were stomatitis, amenorrhoea, pneumonia, neutropenia, pyrexia, gastroenteritis viral and cellulitis.
De hyppigste grad 3/4-bivirkninger (≥ 5 %) var neutropeni, pneumoni, trombocytopeni og febril neutropeni.
The most common grade 3/4 adverse reactions (≥ 5%) were neutropenia, pneumonia, thrombocytopenia, and febrile neutropenia.
De hyppigste infusionsreaktioner (≥ 1,0 %) i Perjeta-gruppen var pyreksi, kulderystelser, træthed, hovedpine, asteni, overfølsomhed og opkastning.
The most common infusion reactions (≥ 1.0%) in the Perjeta-treated group were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity and vomiting.
De hyppigste NCI-CTCAE (version 3) grad 3-4 bivirkninger (> 10 %) var neutropeni, febril neutropeni og leukopeni, og de hyppigste alvorlige bivirkninger var febril neutropeni, neutropeni og diarré.
The most common NCI-CTCAE v.3 Grade 3-4 ADRs (> 10%) were neutropenia, febrile neutropenia and leucopenia, and the most common serious adverse events were febrile neutropenia, neutropenia and diarrhoea.
De hyppigste rapporterede bivirkninger (almindelig hyppighed (≥1/100 til <1/10)) er: Svampeinfektioner, urinvejsinfektion, candida-infektion, anæmi, angst, insomni, svimmelhed, hovedpine, hypertension, hypotension, gastrointestinale og abdominale smerter, kvalme, opkastning, obstipation, diarré, flatulens, oppustethed og distension, unormale leverfunktionstest (øget alanin- aminotransferase (ALAT), aspartat-aminotransferase (ASAT) og basisk fosfatase (ALP)), udslæt, pruritus, ekstremitetssmerter, forhøjet serumkreatinkinase (CK), reaktioner ved infusionsstedet, pyreksi, asteni.
The most frequently reported adverse reactions (frequency common (≥ 1/100 to < 1/10)) are: Fungal infections, urinary tract infection, candida infection, anaemia, anxiety, insomnia, dizziness, headache, hypertension, hypotension, gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension, liver function tests abnormal (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)), rash, pruritus, limb pain, serum creatine phosphokinase (CPK) increased, infusion site reactions, pyrexia, asthenia.
De hyppigste symptomer på en infusionsreaktion var feber, kulderystelser og hypertension.
The most common symptoms of an infusion reaction included fever, chills, and hypertension.
De hyppigste symptomer, der kan opstå efter, du har taget for meget BiResp Spiromax, er rysten, hovedpine eller hurtig hjerterytme (puls).
The most common symptoms that may occur after if you use more BiResp Spiromax than you should are trembling, headache or a rapid heartbeat.
De hyppigste symptomer, der kan opstå efter, du har taget for meget DuoResp Spiromax, er rysten, hovedpine eller hurtig hjerterytme (puls).
The most common symptoms that may occur after if you use more DuoResp Spiromax than you should are trembling, headache or a rapid heartbeat.
De hyppigste tidligere behandlinger inkluderede pemetrexed (38 %), gemcitabin (25 %), taxan (24 %) og bevacizumab (14 %), 22 % af patienterne havde tidligere fået vedligeholdelsesbehandling.
The most common prior therapies included pemetrexed (38%), gemcitabine (25%), taxane (24%), and bevacizumab (14%); 22% of patients received prior maintenance therapy.
De hyppigste virkninger, der medførte standsning af behandlingen, var kredsløbsproblemer, herunder forhøjet blodtryk, infektioner, træthed, diarré, dehydrering, stomatitis, neutropeni, proteinuri og lungeemboli (en blodprop i et kar, der forsyner lungerne).
The most common effects that led to treatment being permanently stopped were problems with the circulation including hypertension, infections, fatigue, diarrhoea, dehydration, stomatitis, neutropenia, proteinuria, and pulmonary embolism (a clot in a blood vessel supplying the lungs).
De hyppigste årsager til de indberettede TRM’er/NRM’er var infektion/sepsis, GVHD, lungesygdomme og organsvigt.
The most frequent causes of reported TRM/NRMs were infection/sepsis, GVHD, pulmonary disorders and organ failure.
De hyppigste årsager til ophør af behandlingen med MULTAQ var gastrointestinale forstyrrelser (3,2 % af patienter mod 1,8 % i placebogruppen).
The most common reasons for discontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2% of patients versus 1.8% in the placebo group).
De hyppiste bivirkninger (med en frekvens ≥1%) hos Revatio-patienter (kombinerede doser) og med en frekvens på > 1% i forhold til placebo-patienter var pyreksi, øvre luftvejsinfektioner (hver 11,5%), opkastning (10,9%), kraftigere erektion (herunder spontane erektioner hos drenge) (9,0%), kvalme, bronkitis (hver 4,6%), pharyngitis (4,0%), næseflåd (3,4%) samt pneumoni og rhinitis (hver 2,9%).
The most common adverse reactions that occurred (with a frequency ≥ 1 %) in Revatio patients (combined doses) and with a frequency > 1 % over placebo patients were pyrexia, upper respiratory tract infection (each 11.5%), vomiting (10.9%), erection increased (including spontaneous penile erections in male subjects) (9.0%), nausea, bronchitis (each 4.6%), pharyngitis (4.0%), rhinorrhoea (3.4%), and pneumonia, rhinitis (each 2.9%).
De hårde kapsler (længde ca.
The hard capsules (length approx.